p16, cyclin D1 and retinoblastoma protein (pRB) regulate G1 to S transition and are commonly targeted in various cancers. However, few studies have simultaneously examined all components of the p16/cyclin D1/pRB pathway (RB pathway) in hepatocellular carcinoma (HCC). To clarify the role of the disruption of the RB pathway in HCC, we analyzed p16, pRB and cyclin D1 in 47 HCCs. Inactivation of p16 was detected in 30 of 47 HCCs (64%) by Western blot analysis and significantly correlated with hypermethylation of the promoter of this gene. pRB expression was found to be absent in 13 of 47 HCCs (28%) by immunohistochemistry. We found that 38 of 47 HCCs (81%) contained at least one inactivation in either pRB or p16. Furthermore, there was a significant inverse correlation between p16 and pRB inactivation (p = 0.041). Overexpression of cyclin D1 was detected in 5 of 47 HCCs (11%) by immunohistochemistry. The cases with cyclin D1 overexpression exhibited an advanced clinicopathological appearance and also contained inactivation of pRB and/or p16. These findings suggest that inactivation of pRB and/or p16 is a major event in human hepatocarcinogenesis, while cyclin D1 overexpression may confer additional growth advantages to the tumor in addition to pRB and/or p16 inactivation in HCC.

Keywords:
Hepatocellular carcinoma, p16, Retinoblastoma protein, Cyclin D1, p16/cyclin D1/retinoblastoma protein pathway
1.
Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC: Increase in primary liver cancer in the UK, 1979–94. Lancet 1997;350:1142–1143.
2.
Deuffic S, Poynard T, Buffat L, Valleron AJ: Trends in primary liver cancer. Lancet 1998;351:214–216.
3.
El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.
4.
Pardee AB: G1 events and regulation of cell proliferation. Science 1989;246:603–608.
5.
Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704–707.
6.
Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR: The E2F transcription factor is a cellular target for the RB protein. Cell 1991;65:1053–1061.
7.
Sherr CJ: G1 phase progression: Cycling on cue. Cell 1994;79:551–555.
8.
Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitiors come of age. Cell 1994;79:573–582.
9.
Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995;81:323–330.
10.
Lukas J, Aagaard L, Strauss M, Bartek J: Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995;55:4818–4823.
11.
Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon H-E, Matsuda H: Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 1998;79:111–115.
12.
Okami K, Reed AL, Cairns P, Koch WM, Westra WH, Wehage S, Jen J, Sidransky D: Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999;18:3541–3545.
13.
Zhang X, Xu H-J, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu S-X, Benedict WF, Sekiya T: Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177–4182.
14.
Hui A-M, Li X, Makuuchi M, Takayama T, Kubota K: Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int J Cancer 1999;84:604–608.
15.
Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M, Ishizaki K: Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994;54:3107–3110.
16.
Zhang Y-J, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993;196:1010–1016.
17.
Hui A-M, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, Hirohashi S: Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996;24:575–579.
18.
Liew CT, Li H-M, Lo K-W, Leow CK, Chan JYH, Hin LY, Lau WY, Lai PBS, Lim BK, Huang J, Leung WT, Wu S, Lee JCK: High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999;18:789–795.
19.
Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H: p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999;116:394–400.
20.
Kita R, Nishida N, Fukuda Y, Azechi H, Matsuoka Y, Komeda T, Sando T, Nakao K, Ishizaki K: Infrequent alterations of the p16INK4A gene in liver cancer. Int J Cancer 1996;67:176–180.
21.
Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 3, revised. Tokyo, Kanehara Press, 1992.
22.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1989, pp 9.6–9.24, 18.30–18.34.
23.
Clark SJ, Harrison J, Paul CL, Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990–2997.
24.
Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW: Low frequency of p16/CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors. Cancer Res 1997;57:5336–5347.
25.
Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M: Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 1995;55:20–23.
26.
Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150–153.
27.
Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994;54:6078–6082.
28.
Fang X, Jin X, Xu H-J, Liu L, Peng H-Q, Hogg D, Roth JA, Yu Y, Xu F, Bast RC, Mills GB: Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 1998;16:1–8.
29.
Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90–99.
30.
Donnellan R, Chetty R: Cyclin D1 and human neoplasia. Mol Pathol 1998;51:1–7.
31.
Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ: Both rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84–88.
32.
Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, Kajiyama G, Ide T: Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinoma. Cancer Res 1995;55:2734–2736.
33.
Nakashio R, Kitamoto M, Tahara H, Nakanishi T, Ide T, Kajiyama G: Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinoma. Int J Cancer 1997;74:141–147.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.